Actively Recruiting
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Led by University Hospital, Bordeaux · Updated on 2025-07-30
120
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.
CONDITIONS
Official Title
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Polycythemia Vera, Essential Thrombocythemia, or Primary Myelofibrosis
- Have DNA extracted from purified granulocytes collected at diagnosis
- Not currently receiving treatment that impacts DNA methylation such as chemotherapy or immunosuppressants
- For control subjects without MPN: no hematological malignancy and tested for JAK2V617F mutation due to reactive thrombocytosis or secondary polycythemia
- Control subjects also must not be receiving treatments affecting DNA methylation
You will not qualify if you...
- Diagnosed with conditions other than Polycythemia Vera, Essential Thrombocythemia, or Primary Myelofibrosis
- No purified granulocyte DNA available from time of diagnosis
- Receiving cytoreductive drugs, demethylating agents, chemotherapy, or immunosuppressive therapy at DNA sampling
- Less than 2 years of follow-up after diagnosis
- For control subjects: presence of hematological malignancy or solid cancer
- Control subjects receiving treatments affecting DNA methylation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux, service Hématologie Biologique
Bordeaux, France
Actively Recruiting
Research Team
O
Olivier MANSIER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here